Cipla Medpro nabs $33M drug contract; Roche's subQ MabThera launch triggers Halozyme payment; Auxilium snaps up Canada's QLT;

@FiercePharma: Special: The top 5 vaccines by 2020. Report | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: Actavis says growing production at plant in Malta called for new warehouse. More | Follow @EricPFierce

@CarlyHFierce: Here's this week's issue of FierceVaccines. Hint: It's a good one. Issue | Follow @CarlyHFierce

> South Africa's government awarded Cipla Medpro a $32.6 million contract for respiratory drugs as part of an effort to cut deaths from asthma. Report

> Roche's ($RHHBY) European launch of MabThera in a subcutaneous form triggered at $5 million milestone payment to Halozyme ($HALO). Report

> Auxilium Pharmaceuticals ($AUXL) says it's buying the Canadian eye drug maker QLT to snag an experimental drug for retinal diseases. Report

> Actavis ($ACT) asked the FDA to approve its version of Acorda Therapeutics' ($ACOR) multiple sclerosis drug Ampyra; Acorda says it will defend its patent on the med. Report

> The FDA warned that popular over-the-counter acne products such as Proactiv can cause rare but serious and life-threatening allergic reactions. Report

> Amphastar Pharmaceuticals ($AMPH) said its initial public offering would be priced at $7 per share, which would yield about $56 million. Report

Medical Device News

@FierceMedDev: Check out our newest special report: Top 10 med tech R&D budgets. Read | Follow @FierceMedDev

@StacyALawrence: Newly public Inogen gains on FDA clearance for home oxygen device. Story | Follow @StacyALawrence

@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. More via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Ultrasound therapy outfit rakes in $2M for wearable chronic pain device. Story | Follow @EmilyWFierce

> Danaher demurs on M&A, looks to China, Brazil and Russia. Piece

> $125M IPO planned for former BMS medical imaging unit. News

Biotech News

@FierceBiotech: Polaris preps for a $400M fund to back a new wave of biotechs. More | Follow @FierceBiotech

@JohnCFierce: Biotech vets target $43M round to debut new antifungal venture. Story | Follow @JohnCFierce

@DamianFierce: We need to commission an inversion graphic for future stories. Article | Follow @DamianFierce

@EmilyMFierce: Gives a new meaning to YOLO: The Higgs Boson should have crushed the universe. More | Follow @EmilyMFierce

> Boehringer bags a 'breakthrough' tag for its Pradaxa antidote. Story

> Auxilium eyes a Canadian biotech for a tax-cutting merger. More

> FDA experts spurn AstraZeneca's pitch for ovarian cancer drug olaparib. Article

Vaccines News

> Italian officials probe Novartis for possible flu vaccine pricing fraud. Story

> FDA slaps Glaxo with warning letter for FluLaval plant. More

> CDC committee recommends AZ's FluMist over flu shot in children. Article

> The top 5 vaccines by 2020. Report

> Feds charge researcher in HIV vaccine fraud case. More

> Reuters: Sanofi plans to put dengue program into separate unit. News

Pharma Manufacturing News

> FDA finds contamination issues at GSK vax plant. More

> India production expert urges excellence from drugmakers. Story

> New Indian government looks to help small players finance upgrades. Article

> Sanofi buys Dubai's Globalpharma to produce generics in the Middle East. News

> Actavis opens $18M warehouse on Malta. Report

And Finally... Doctors should monitor more stroke patients for atrial fibrillation that may have gone undiagnosed. Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.